Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients With Stage II-III Non-Small Cell Lung Cancer
The study is designed to determine whether an accelerated course of hypofractionated radiation therapy with daily image guidance and motion assessment/control will allow more effective treatment of poor performance status patients with stage II-III NSCLC, who would benefit from local therapy compared to standard radiation therapy (60 Gy in 2 Gy per fraction).
Checked against the public recordLast updated Jan 17, 2024 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 3
- Sponsor
- University of Texas Southwestern Medical Center
- Interventions being studied
- Radiation: Radiation Therapy; Radiation: Conventional radiation
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * All patients must be willing and capable to provide informed consent to participate in the protocol. * Patients must have appropriate staging studies identifying them as AJCC stage II or III non small cell lung cancer, (according to AJCC Staging, 6th edition; see appendix III), or recurrent non small cell lung cancer. Histologic confirmation of cancer will be required by biopsy or cytology within 6 months of study entry. * Patients must have the potential for benefit from local therapy (at the discretion of the investigator). * The patient's Zubrod performance status must be 2 or greater OR patients with Zubrod performance status 0-1 and weight loss \>10% are considered eligible. In addition, patients determined to be medically unfit or refusing combined modality therapy are eligible. * Age ≥ 18. * Patients must have measurable or evaluable disease. * Women of childbearing potential and male participants must agree to use an effective method of contraception. * Patients must sign study specific informed consent prior to study entry. * Patients must not have plans for concurrent chemoradiation therapy. * Patients must complete all required pretreatment evaluations Exclusion Criteria: * Total (aggregate) gross tumor volume \> 500 cm3 (500 cc's or 0.5 Liters) * Prior radiotherapy to the region of the study cancer that would result in direct overlap of radiation therapy fields. * Chemotherapy given within one week of study registration. * Pregnant or lactating women, as treatment involves unforeseeable risks to the embryo or fetus.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Georgetown Cancer Center (Austin Cancer Center)Austin, Texas
- University of Texas Southwestern Medical CenterDallas, Texas
- Md Anderson Cancer CenterHouston, Texas
- Baylor Research Institute Dallas, Baylor IrvingIrving, Texas
- Texas Oncology - ShermanSherman, Texas
- Scott & White Memorial TempleTemple, Texas
- Texas Oncology - TylerTyler, Texas
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 17, 2024. Always confirm current availability with the study team.